Investigating how certain enzymes affect bladder cancer mutations
The Mutagenic Effects of APOBEC3A and APOBEC3B in Urothelial Carcinoma
This study is looking at how two specific enzymes might cause changes in bladder cancer, which could help explain why some tumors grow faster and resist treatment, and it's designed for people interested in understanding more about their cancer and potential therapies.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10825932 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of two enzymes, APOBEC3A and APOBEC3B, in causing mutations in urothelial carcinoma, the most common type of bladder cancer. By studying how these enzymes contribute to tumor evolution and treatment resistance, the research aims to clarify their individual impacts on cancer progression. The approach involves using mouse bladder cancer cell lines to observe the mutagenic effects of these enzymes and their influence on the tumor's response to immune therapies. This could provide insights into why some tumors are more aggressive and resistant to treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with urothelial carcinoma, particularly those with advanced or metastatic disease.
Not a fit: Patients with non-urothelial types of bladder cancer or those without active disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for bladder cancer by identifying specific targets for therapy.
How similar studies have performed: Previous research has shown that targeting mutagenic processes in cancer can lead to significant advancements in treatment, suggesting this approach may yield valuable insights.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Sturdivant, Michael Sean — Univ of North Carolina Chapel Hill
- Study coordinator: Sturdivant, Michael Sean
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.